Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

Elutia (Nasdaq: ELUT) earned 2026 Great Place to Work Certification, recognizing high-trust culture, sustained engagement, and retention in a regulated, innovation-driven company.

Rhea-AI Summary

Elutia (Nasdaq: ELUT) earned 2026 Great Place to Work Certification, recognizing high-trust culture, sustained engagement, and retention in a regulated, innovation-driven company.

Workforce highlights: women 54% of employees and 62% of leaders, median tenure 6.3 years, half hold advanced degrees, one-third hold doctorates. The release cites prior leadership commercial successes, including an $88 million asset sale and $1.5 billion in products brought to market.

Argus Feb 18 session

+4.35% close to close Open Argus

Details

News Market Reaction – ELUT

In the Feb 18 session, ELUT gained 4.35%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Elutia’s certification as a Great Place to Work®, underscoring an exper...

Analysis

This announcement highlights Elutia’s certification as a Great Place to Work®, underscoring an experienced team with a median tenure of 6.3 years, substantial female leadership representation at 62%, and products that have contributed over $1.5 billion in sales historically. In the broader context of recent asset sales and NXT-41x development updates, investors may watch how this strong culture supports execution on upcoming clinical, regulatory, and commercial milestones.

Key Figures

EluPro sale: $88 million Women workforce share: 54% Women leadership share: 62% +5 more

EluPro sale

$88 million

EluPro™ acquired by Boston Scientific

Women workforce share

54%

Proportion of Elutia workforce that are women

Women leadership share

62%

Proportion of leadership roles held by women

Median tenure

6.3 years

Employee median tenure at Elutia

Company age

10 years

Time since Elutia was founded

Product sales impact

$1.5 billion

Sales generated by products Dr. Williams brought to market

Turnover reduction

50% lower

Typical turnover in high-trust cultures per Great Place To Work®

Survey research period

30 years

Great Place To Work® survey methodology development

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Prelim Q4 results

   24h Move

   -4.8%

   Preliminary Q4 2025 results, debt repayment, and NXT-41x milestone outlook.

2. Jan 09

   Conference presentation

   24h Move

   +4.7%

   Presentation on NXT-41x biomatrix at Global BioInnovation Forum.

3. Nov 06

   Q3 earnings & sale

   24h Move

   -5.0%

   Q3 2025 results and closing of $88M BioEnvelope sale to Boston Scientific.

4. Oct 23

   Earnings date notice

   24h Move

   -0.7%

   Announcement of Q3 2025 earnings release and conference call schedule.

5. Oct 14

   Investor conference

   24h Move

   +0.9%

   CEO presentation and 1x1 investor meetings at LD Micro Main Event XIX.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

drug-eluting biomatrix, biologic products, breast cancer

3 terms

drug-eluting biomatrix medical

"Elutia Inc. (Nasdaq: ELUT) … a pioneer in drug-eluting biomatrix technologies"

A drug-eluting biomatrix is a medical implant or coating made of biocompatible material that slowly releases a drug at a controlled rate where it is placed in the body, like a sponge that steadily releases medicine into surrounding tissue. For investors, it matters because such technology can improve treatment effectiveness, reduce side effects and repeat procedures, and therefore influence product value, regulatory risk and long-term revenue potential for medical-device and pharmaceutical companies.

biologic products medical

"Over her career she has developed advanced biologic products across multiple therapeutic areas"

Biologic products are medicines and vaccines made from living cells, organisms, or their components rather than simple chemical recipes, more like a handcrafted loaf compared with a mass‑produced cookie. They matter to investors because they are costly and complex to develop and manufacture, protected by strong regulatory rules and exclusivity, and small changes can affect supply, pricing, and long‑term revenue streams for companies.

breast cancer medical

"to improve outcomes for women with breast cancer? Explore Careers - Elutia."

Breast cancer is a disease in which cells in the breast start growing uncontrollably, forming lumps or tumors that can invade nearby tissue or spread elsewhere in the body—like a patch of weeds overtaking a garden if not removed. For investors, breast cancer is important because diagnosis rates, new treatments, drug approvals and clinical trial results can quickly change demand for drugs, diagnostics and care, affecting revenues, valuations and risk for healthcare and related companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work^®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention support consistent execution in regulated, innovation-driven industries.

“Elutia isn’t for everyone,” said Dana Yoo, PhD, VP of Product Development. “The bar is high, and the work is hard. But the first time I saw our technology used in surgery, I understood why. This wasn’t an experiment. It was someone’s future. It’s demanding, but if you want your work to matter, there’s no place better.” Dr. Yoo has been with Elutia for six years. Over her career she has developed advanced biologic products across multiple therapeutic areas, from orthopedics to wound care, and most recently led the development of EluPro™, which was acquired by Boston Scientific for $88 million.

Elutia’s team is defined by a simple standard: excellence. Elutia hires for intellect and drive, and people stay because of the mission and the team. That commitment is reflected in the depth and stability of the organization. Women comprise 54% of the workforce and 62% of leadership roles. Half of Elutia’s team members hold advanced degrees, and one-third hold doctorates. In a company founded just 10 years ago, a median tenure of 6.3 years reflects continuity throughout the company’s evolution.

“This team executes,” said Fletcher Brehler, Senior Director, Strategic Marketing. “We debate hard, align fast, and move. This isn’t chaos dressed up as innovation. It’s disciplined professionals who know exactly what we’re building and why. That kind of clarity is rare, and it makes even the hardest challenges fun.” Fletcher has been with Elutia for seven years and has been a driving force behind the product launch and success of the SimpliDerm business unit.

“Elutia is special because of the CRU,” said Michelle Williams, PhD, Chief Scientific Officer. “We hold ourselves to uncompromising standards because our patients depend on it. Our mission to humanize medicine so patients can thrive without compromise requires developing first-in-class products and disciplined regulatory execution. It’s hard, but for those who want their efforts to truly matter, Elutia is more than a great place to work. For me, it’s the only place.” Dr. Williams is a co-founder and corporate officer of Elutia and has, over her career, invented and brought products to market that have generated more than $1.5 billion in sales.

Great Place To Work^® is the global authority on workplace culture, employee experience, and leadership behaviors proven to drive market-leading revenue, employee retention, and increased innovation. This data-driven certification identifies high-trust cultures that typically achieve 50% lower turnover and significantly outperform industry benchmarks for performance.

We're hiring!
Want to join a mission-driven CRU of A-players working relentlessly to improve outcomes for women with breast cancer? Explore Careers - Elutia.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

About Great Place to Work Certification™
Great Place To Work^® Certification™ is the most definitive “employer-of-choice” recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified.

About Great Place To Work^®
As the global authority on workplace culture, Great Place To Work^® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List.

Investors:
Elutia Investor Relations
ir@elutia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Elutia's 2026 Great Place to Work Certification mean for ELUT investors?

It signals a recognized high-trust workplace culture that can support execution and retention. According to the company, certification reflects sustained engagement and stability that may help operational continuity and product development timelines.

What workforce metrics did Elutia (ELUT) disclose with the 2026 certification announcement?

Elutia reported women comprise 54% of employees and 62% of leadership roles. According to the company, median tenure is 6.3 years; half have advanced degrees and one-third hold doctorates.

Does Elutia (ELUT) cite any commercial track record in the Feb 18, 2026 announcement?

Yes, the company referenced leadership commercial experience, including an $88 million acquisition and $1.5 billion in product sales. According to the company, these examples underscore team experience and execution history.

How might Great Place to Work Certification affect Elutia's (ELUT) hiring and retention?

Certification may improve recruiting and lower turnover by signaling strong culture and engagement. According to the company, high-trust cultures typically show sustained engagement and improved retention supporting consistent execution.

Where can prospective employees learn about careers at Elutia (ELUT) after the certification?

Prospective applicants are directed to explore open roles via Elutia's careers channel. According to the company, they are hiring mission-driven professionals focused on improving outcomes for women with breast cancer.